Enhancing Detection of Circulating Tumor Cells with Activating KRAS Oncogene in Patients with Colorectal Cancer by Weighted Chemiluminescent Membrane Array Method

Abstract

These findings also highlight the need to prompt further prospective studies on more cases of CRC to further establish the clinical relevance of activating KRAS mutation detection from peripheral blood in anti- EGFR-based chemotherapy that uses activating KRAS detection chips and the WCHMA analysis method.

A prospective study comparing multi-gene biomarker chip and serum carcinoembryonic antigen in the postoperative surveillance for patients with stage I–III colorectal cancer

“…In the present study, the specificity (92.0%) and accuracy (91.3%), but not the sensitivity (87.5%), of the biomarker chip were similar to those reported in previous studies that used the WEnCA platform [18][19][20][21][22]. The false-positive rate of the biomarker chip in early prediction of postoperative relapse was 32.3%; nevertheless, postoperative serum CEA levels showed a higher false-positive rate (59.2%).…”

“…04 003 301.1). In order to implement the clinical application of specific gene groups, the oligonucleotide sequences of top 19 highly overexpressed target genes of the 71 genes were selected (Table 2), as described previously [18][19][20]; they were designed using the Oligo Explorer software program (Gene Link, Inc. New York, USA).…”

“…Each overexpressed spot was then multiplied by the respective weighted values ranging from 1 to 4, according to the principle described previously [18][19][20][21][22].…”

Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer

“…Frequently, the material is not available or is found insufficient for molecular analysis in advanced stages of the disease. 1 In addition, initial primary tumor specimens are not always representative of the metastasis that can occur many years after the resection of the primary tumor. 2 After primary tumor biopsy or surgical removal, many other mutations can be acquired and other specific abnormalities found in the primary tumor can be lost.…”

Clinical Application of Automatic Gene Chip Analyzer (WEnCA-Chipball) for Mutant Kras Detection in Peripheral Circulating Cancer Cells of Cancer Patients

“…The traditional techniques such as direct sequencing, polymerase chain reaction and restriction fragment length polymorphism are complicated and can easily be used only in tissue samples, which limits KRAS mutation detection in clinical applications. In order to improve the mutant KRAS detection efficiency, we successfully developed an Activating KRAS Detection Chip and colorimetric membrane array (CLMA) technique capable of detecting KRAS mutation status by screening circulating carcinoma cells in the surrounding bloodstream (Chen et al, 2005;Wang et al, 2006;Chong et al, 2007;Yen et al, 2009;Yang et al, 2010). However, the sensitivity still needs further improvement.…”